Broker Offer Results & Director/PDMR Subscription

Further to the announcement made at 7.00 a.m. on 9 December 2024 by the Company in connection with the Fundraising to raise up to £1,573,000 (before expenses) (the "Fundraise Announcement"), ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, announces that a total of 38,461,538 Broker Offer Shares have been subscribed for at the Issue Price in connection with the conditional Broker Offer, raising £250,000.

Following the closing of the Broker Offer, the total gross proceeds for the Company from the conditional Fundraising, comprising the Placing Shares, the Subscription Shares and the Broker Offer Shares (together the "New Ordinary Shares"), are £1,573,000.

Director/PDMR Subscription

As set out in the announcement of 9 December 2024, Mark Eccleston, CEO of the Company has informed the Company that, in addition to his participation in the Subscription, he has subscribed for a further 3,076,923 Broker Offer Shares under the Broker Offer. Details of his shareholdings following completion of the Fundraising and subject to shareholder approval at the General Meeting, are set out below:

1of which, 9,846,145 New Ordinary Shares have been subscribed for by Mark Eccleston directly, 5,538,470 New Ordinary Shares have been subscribed for by OncoLytika Ltd (a company in which Dr. Eccleston is interested) and 2,307,692 New Ordinary Shares have been subscribed for by Mark Eccleston's partner.

Admission

Subject to shareholder approval at the General Meeting, the Company will make an application to the London Stock Exchange plc for th New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission of the New Ordinary Shares will become effective and dealings will commence at 8.00 a.m. on or around 31 December 2024. The New Ordinary Shares will rank pari passu with the Existing Shares.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, subject to shareholder approval at the General Meeting and following Admission, the enlarged issued share capital of the Company will comprise 374,348,672 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 9 December 2024.